1. Home
  2. YDESW vs HUMAW Comparison

YDESW vs HUMAW Comparison

Compare YDESW & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDESW

YD Bio Limited Warrants

HOLD

Current Price

$0.25

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

HOLD

Current Price

$0.00

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDESW
HUMAW
Founded
N/A
2004
Country
United States
United States
Employees
15
184
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
YDESW
HUMAW
Price
$0.25
$0.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.9K
18.2K
Earning Date
N/A
03-21-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.01
52 Week High
$2.85
$0.60

Technical Indicators

Market Signals
Indicator
YDESW
HUMAW
Relative Strength Index (RSI) 25.37 31.94
Support Level N/A N/A
Resistance Level $0.58 $0.12
Average True Range (ATR) 0.02 0.01
MACD -0.01 -0.00
Stochastic Oscillator 0.00 5.90

Price Performance

Historical Comparison
YDESW
HUMAW

About YDESW YD Bio Limited Warrants

YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: